← Evidence map

ArticlePharmacoEconomics2006

A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy.

Aslam H Anis et al.PubMed ↗Publisher ↗

No numbers read from the abstract.

7 papers cite it

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

this papercites it

A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy. | OpenQuestion